These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 10991968

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure.
    Preston KL, Bigelow GE.
    J Pharmacol Exp Ther; 1994 Oct; 271(1):48-60. PubMed ID: 7525929
    [Abstract] [Full Text] [Related]

  • 3. Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination.
    Preston KL, Liebson IA, Bigelow GE.
    J Pharmacol Exp Ther; 1992 Apr; 261(1):62-71. PubMed ID: 1373189
    [Abstract] [Full Text] [Related]

  • 4. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
    Jones HE, Bigelow GE, Preston KL.
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1350-61. PubMed ID: 10336526
    [Abstract] [Full Text] [Related]

  • 5. Drug discrimination in human postaddicts: agonist-antagonist opioids.
    Preston KL, Bigelow GE, Bickel WK, Liebson IA.
    J Pharmacol Exp Ther; 1989 Jul; 250(1):184-96. PubMed ID: 2473187
    [Abstract] [Full Text] [Related]

  • 6. Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline.
    Preston KL, Bigelow GE, Bickel W, Liebson IA.
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1002-9. PubMed ID: 2447262
    [Abstract] [Full Text] [Related]

  • 7. Drug discrimination in human post-addicts: agonist/antagonist opioids.
    Preston K, Bigelow G, Bickel W, Liebson I.
    NIDA Res Monogr; 1988 Dec; 81():209-15. PubMed ID: 2457160
    [No Abstract] [Full Text] [Related]

  • 8. Assessment of buprenorphine in a drug discrimination procedure in humans.
    Bigelow GE, Preston KL.
    NIDA Res Monogr; 1992 Dec; 121():28-37. PubMed ID: 1406908
    [Abstract] [Full Text] [Related]

  • 9. Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect.
    Bickel WK, Bigelow GE, Preston KL, Liebson IA.
    J Pharmacol Exp Ther; 1989 Dec; 251(3):1053-63. PubMed ID: 2481029
    [Abstract] [Full Text] [Related]

  • 10. Discriminative stimulus effects of opioids in pigeons trained to discriminate fentanyl, bremazocine and water: evidence of pharmacological selectivity.
    Picker MJ, Cook CD.
    Behav Pharmacol; 1997 Jun; 8(2-3):160-73. PubMed ID: 9833011
    [Abstract] [Full Text] [Related]

  • 11. Agonist and antagonist effects of mixed action opioids in the pigeon drug discrimination procedure: influence of training dose, intrinsic efficacy and interanimal differences.
    Picker MJ, Yarbrough J, Hughes CE, Smith MA, Morgan D, Dykstra LA.
    J Pharmacol Exp Ther; 1993 Aug; 266(2):756-67. PubMed ID: 8394915
    [Abstract] [Full Text] [Related]

  • 12. Kappa agonist and antagonist properties of mixed action opioids in a pigeon drug discrimination procedure.
    Picker MJ.
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1190-8. PubMed ID: 8138931
    [Abstract] [Full Text] [Related]

  • 13. Antagonist effects of nalbuphine in opioid-dependent human volunteers.
    Preston KL, Bigelow GE, Liebson IA.
    J Pharmacol Exp Ther; 1989 Mar; 248(3):929-37. PubMed ID: 2467983
    [Abstract] [Full Text] [Related]

  • 14. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans.
    Walsh SL, Sullivan JT, Preston KL, Garner JE, Bigelow GE.
    J Pharmacol Exp Ther; 1996 Nov; 279(2):524-38. PubMed ID: 8930154
    [Abstract] [Full Text] [Related]

  • 15. Pretreatment with hydromorphone, a mu-opioid agonist, does not alter the acute behavioral and physiological effects of ethanol in humans.
    Rush CR.
    Alcohol Clin Exp Res; 2001 Jan; 25(1):9-17. PubMed ID: 11198720
    [Abstract] [Full Text] [Related]

  • 16. Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers.
    Preston KL, Bigelow GE.
    J Pharmacol Exp Ther; 1993 Feb; 264(2):813-23. PubMed ID: 7679737
    [Abstract] [Full Text] [Related]

  • 17. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
    Strain EC, Preston KL, Liebson IA, Bigelow GE.
    J Pharmacol Exp Ther; 1993 Nov; 267(2):624-34. PubMed ID: 7504098
    [Abstract] [Full Text] [Related]

  • 18. Opioid discrimination in humans: discriminative and subjective effects of progressively lower training dose.
    Preston KL, Bigelow GE.
    Behav Pharmacol; 1998 Nov; 9(7):533-43. PubMed ID: 9862079
    [Abstract] [Full Text] [Related]

  • 19. Discrimination of butorphanol and nalbuphine in opioid-dependent humans.
    Preston KL, Bigelow GE, Liebson IA.
    Pharmacol Biochem Behav; 1990 Nov; 37(3):511-22. PubMed ID: 1708145
    [Abstract] [Full Text] [Related]

  • 20. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.
    Carroll CP, Walsh SL, Bigelow GE, Strain EC, Preston KL.
    Exp Clin Psychopharmacol; 2006 May; 14(2):109-20. PubMed ID: 16756415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.